Positive pretransplantation cytomegalovirus serology is a risk factor for cardiac allograft vasculopathy in children

Circulation

Volumn 115, Issue 13, 2007, Pages 1798-1805

  Hussain, Tarique ^a,b   Burch, Michael ^a   Fenton, Matthew J ^a   Whitmore, Pauline M ^a   Rees, Philip ^a   Elliott, Martin ^a   Aurora, Paul ^a  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^b NONE   (United Kingdom)

Author keywords

Coronary disease; Pediatrics; Transplantation; Viruses

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CARDIAC ALLOGRAFT VASCULOPATHY; CAUSE OF DEATH; CHILD; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DONOR; FEMALE; FOLLOW UP; GRAFT FAILURE; HEART DEATH; HEART TRANSPLANTATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NEWBORN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; SERODIAGNOSIS; SEX DIFFERENCE; ALLOTRANSPLANTATION; BLOOD; CYTOMEGALIC INCLUSION BODY DISEASE; DISEASE FREE SURVIVAL; EVALUATION; GRAFT SURVIVAL; IMMUNOLOGY; MORTALITY; PATHOGENICITY; POSTOPERATIVE COMPLICATION; PREDICTION AND FORECASTING; PREMEDICATION; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SAMPLE SIZE; TREATMENT OUTCOME; VIROLOGY; VIRUS INFECTION; VIRUS LATENCY;

ANTIVIRUS AGENT; DRUG DERIVATIVE; GANCICLOVIR; LYMPHOCYTE ANTIBODY; VALGANCICLOVIR; VIRUS ANTIBODY;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; ANTILYMPHOCYTE SERUM; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; CORONARY DISEASE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GANCICLOVIR; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMANS; INFANT; INFANT, NEWBORN; MALE; POSTOPERATIVE COMPLICATIONS; PREDICTIVE VALUE OF TESTS; PREMEDICATION; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SAMPLE SIZE; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIRUS DISEASES; VIRUS LATENCY;

EID: 34247227533     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.106.627570     Document Type: Article

References (38)

1. Costanzo MR, Naftel DC, Pritzker MR, Heilman JK III, Boehmer JP, Brozena SC, Dec GW, Ventura HO, Kirklin JK, Bourge RC, Miller LW. Heart transplant coronary artery disease detected by coronary angiography: a multiinstitutional study of preoperative donor and recipient risk factors: Cardiac Transplant Research Database. J Heart Lung Transplant. 1998;17:744-753.
2. Kobashigawa JA, Tobis JM, Starling RC, Tuzcu EM, Smith AL, Valantine HA, Yeung AC, Mehra MR, Anzai H, Oeser BT, Abeywickrama KH, Murphy J, Cretin N. Multicenter intravascular ultrasound validation study among heart transplant recipients: outcomes after five years. J Am Coll Cardiol. 2005;45:1532-1537.
3. Pahl E, Naftel DC, Kuhn MA, Shaddy RE, Morrow WR, Canter CE, Kirklin J. The impact and outcome of transplant coronary artery disease in a pediatric population: a 9-year multi-institutional study. J Heart Lung Transplant. 2005;24:645-651.
4. Taylor DO, Edwards LB, Boucek MM, Trulock EP, Deng MC, Keck BM, Hertz MI. Registry of the International Society for Heart and Lung Transplantation: twenty-second official adult heart transplant report: 2005. J Heart Lung Transplant. 2005;24:945-955.
5. Boucek MM, Edwards LB, Keck BM, Trulock EP, Taylor DO, Hertz MI. Registry of the International Society for Heart and Lung Transplantation: eighth official pediatric report: 2005. J Heart Lung Transplant. 2005;24:968-982.
6. Maseri A. Inflammation, atherosclerosis, and ischemic events: exploring the hidden side of the moon. N Engl J Med. 1997;336:1014-1016.
7. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J. 1999;138:S419-S420.
8. van der Wal AC, Becker AE, van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 1994;89:36-44.
9. Muhlestein JB, Horne BD, Carlquist JF, Madsen TE, Bair TL, Pearson RR, Anderson JL. Cytomegalovirus seropositivity and C-reactive protein have independent and combined predictive value for mortality in patients with angiographically demonstrated coronary artery disease. Circulation. 2000;102:1917-1923.
10. Eryol NK, Kilic H, Gul A, Ozdogru I, Inanc T, Dogan A, Topsakal R, Basar E. Are the high levels of cytomegalovirus antibodies a determinant in the development of coronary artery disease? Int Heart J. 2005;46:205-209.
11. Blum A, Peleg A, Weinberg M. Anti-cytomegalovirus (CMV) IgG antibody titer in patients with risk factors to atherosclerosis. Clin Exp Med. 2003;3:157-160.
12. Muhlestein JB, Anderson JL. Chronic infection and coronary artery disease. Cardiol Clin. 2003;21:333-362.
13. Chen R, Xiong S, Yang Y, Fu W, Wang Y, Ge J. The relationship between human cytomegalovirus infection and atherosclerosis development. Mol Cell Biochem. 2003;249:91-96.
14. Bork J, Chinnock R, Ogata K, Baum M. Infectious complications in infant heart transplantation. J Heart Lung Transplant. 1993;12:S199-S202.
15. Lemstrom K, Koskinen P, Lautenschlager I, Krogerus L, Nieminen M, Hayry P, Mattila S. Frequency of infections and their relation to episodes of acute rejection among heart allograft recipients. Presse Med. 1994;23:1252-1256.
16. Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, Shumway NE. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA. 1989;261:3561-3566.
17. DeCampli WM, Luikart H, Hunt S, Stinson EB. Characteristics of patients surviving more than ten years after cardiac transplantation. J Thorac Cardiovasc Surg. 1995;109:1103-1114.
18. Fateh-Moghadam S, Bocksch W, Wessely R, Jager G, Hetzer R, Gawaz M. Cytomegalovirus infection status predicts progression of hearttransplant vasculopathy. Transplantation. 2003;76:1470-1474.
19. Loebe M, Schuler S, Spiegelsberger S, Warnecke H, Fleck E, Hetzer R. Cytomegalovirus infection and coronary sclerosis after heart transplantation [in German]. Dtsch Med Wochenschr. 1990;115:1266-1269.
20. McDonald K, Rector TS, Braulin EA, Kubo SH, Olivari MT. Association of coronary artery disease in cardiac transplant recipients with cytomegalovirus infection. Am J Cardiol. 1989;64:359-362.
21. Potena L, Grigioni F, Ortolani P, Magnani G, Marrozzini C, Falchetti E, Barbieri A, Bacchi-Reggiani L, Lazzarotto T, Marzocchi A, Magelli C, Landini MP, Branzi A. Relevance of cytomegalovirus infection and coronary-artery remodeling in the first year after heart transplantation: a prospective three-dimensional intravascular ultrasound study. Transplantation. 2003;75:839-843.
22. Sharples LD, Jackson CH, Parameshwar J, Wallwork J, Large SR. Cardiac allograft vasculopathy after heart transplantation: risk factors and management. Transplantation. 2003;76:679-682.
23. Gao SZ, Hunt SA, Schroeder JS, Alderman EL, Hill IR, Stinson EB. Early development of accelerated graft coronary artery disease: risk factors and course. J Am Coll Cardiol. 1996;28:673-679.
24. Mattila S, Heikkila L, Sipponen J, Verkkala K, Kyosola K, Mattila T, Jarvinen A, Luosto R, Heikkinen L, Ketonen P, Salo J, Nemlander A, Mattila I, Nieminen MS. Heart transplantation in Finland 1985-1995. Ann Chir Gynaecol. 1997;86:113-120.
25. Petrakopoulou P, Kubrich M, Pehlivanli S, Meiser B, Reichart B, von SW, Weis M. Cytomegalovirus infection in heart transplant recipients is associated with impaired endothelial function. Circulation. 2004;110(suppl II):II-207-II-212.
26. Razonable RR, Emery VC. Management of CMV infection and disease in transplant patients. Herpes. 2004;11:77-86.
27. Braunlin EA, Hunter DW, Canter CE, Gutierrez FR, Ring WS, Olivari MT, Titus JL, Spray TL, Bolman RM III. Coronary artery disease in pediatric cardiac transplant recipients receiving triple-drug immunosuppression. Circulation. 1991;84(suppl III):III-303-III-309.
28. Chinnock RE, Baum MF, Larsen R, Bailey L. Rejection management and long-term surveillance of the pediatric heart transplant recipient: the Loma Linda experience. J Heart Lung Transplant. 1993;12:S255-S264.
29. Le BJ, Ladeia A, Vouhe P, Delogu A, Piechaud JF, Sidi D, Tamisier D, Leca F, Pedroni E, Kachaner J. Risk factors of coronary graft disease following heart transplantation in children [in French]. Arch Mal Coeur Vaiss. 1994;87:587-591.
30. Pahl E, Fricker FJ, Armitage J, Griffith BP, Taylor S, Uretsky BF, Beerman LB, Zuberbuhler JR. Coronary arteriosclerosis in pediatric heart transplant survivors: limitation of long-term survival. J Pediatr. 1990;116:177-183.
31. Paavonen T, Mennander A, Lautenschlager I, Mattila S, Hayry P. Endothelialitis and accelerated arteriosclerosis in human heart transplant coronaries. J Heart Lung Transplant. 1993;12:117-122.
32. McGiffin DC, Savunen T, Kirklin JK, Naftel DC, Bourge RC, Paine TD, White-Williams C, Sisto T, Early L. Cardiac transplant coronary artery disease: a multivariable analysis of pretransplantation risk factors for disease development and morbid events. J Thorac Cardiovasc Surg. 1995;109:1081-1088.
33. Kuhn MA, Jutzy KR, Deming DD, Cephus CE, Chinnock RE, Johnston J, Bailey LL, Larsen RL. The medium-term findings in coronary arteries by intravascular ultrasound in infants and children after heart transplantation. J Am Coll Cardiol. 2000;36:250-254.
34. Schowengerdt KO, Naftel DC, Seib PM, Pearce FB, Addonizio LJ, Kirklin JK, Morrow WR; the Pediatric Heart Transplant Study Group. Infection after pediatric heart transplantation: results of a multiinstitutional study. J Heart Lung Transplant. 1997;16:1207-1216.
35. Kirklin JK, Naftel DC, Levine TB, Bourge RC, Pelletier GB, O'Donnell J, Miller LW, Pritzker MR; the Cardiac Transplant Research Database Group. Cytomegalovirus after heart transplantation: risk factors for infection and death: a multiinstitutional study. J Heart Lung Transplant. 1994;13:394-404.
36. Lemstrom K, Sihvola R, Bruggeman C, Hayry P, Koskinen P. Cytomegalovirus infection-enhanced cardiac allograft vasculopathy is abolished by DHPG prophylaxis in the rat. Circulation. 1997;95:2614-2616.
37. Luckraz H, Charman SC, Wreghitt T, Wallwork J, Parameshwar J, Large SR. Does cytomegalovirus status influence acute and chronic rejection in heart transplantation during the ganciclovir prophylaxis era? J Heart Lung Transplant. 2003;22:1023-1027.
38. Valantine HA. The role of viruses in cardiac allograft vasculopathy. Am J Transplant. 2004;4:169-177.